1. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16. 20.
2. National Collaborating Centre for Cancer (UK). Familial Breast Cancer: Classification and Care of People at Risk of Familial Breast Cancer and Management of Breast Cancer and Related Risks in People with a Family History of Breast Cancer [Internet]. Cardiff (UK): National Collaborating Centre for Cancer (UK); 2013 [cited 2020 Feb 18]. (National Institute for Health and Clinical Excellence: Guidance). Available from: http://www.ncbi.nlm.nih.gov/books/NBK247567/.
3. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016;27:v103–10.
4. Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 [Internet]. J Natl Compr Cancer Netw.: JNCCN. 2020 [cited 2020 Dec 8]. Available from: https://pubmed.ncbi.nlm.nih.gov/32259785/.
5. Synthèse - Femmes porteuses d’une mutation de BRCA1 ou BRCA2/Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque - Ref: RECOBRCASYNTH17 | Institut National Du Cancer [Internet]. [cited 2017 Aug 15]. Available from: http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Synthese-Femmes-porteuses-d-une-mutation-de-BRCA1-ou-BRCA2-Detection-precoce-du-cancer-du-sein-et-des-annexes-et-strategies-de-reduction-du-risque.